Cargando…

Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization

Human serum albumin nanoparticles (HSA-NPs) are widely-used drug delivery systems with applications in various diseases, like cancer. For intravenous administration of HSA-NPs, the particle size, surface charge, drug loading and in vitro release kinetics are important parameters for consideration. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomis, Nikita, Westfall, Susan, Farahdel, Leila, Malhotra, Meenakshi, Shum-Tim, Dominique, Prakash, Satya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302621/
https://www.ncbi.nlm.nih.gov/pubmed/28335244
http://dx.doi.org/10.3390/nano6060116
_version_ 1782506580490584064
author Lomis, Nikita
Westfall, Susan
Farahdel, Leila
Malhotra, Meenakshi
Shum-Tim, Dominique
Prakash, Satya
author_facet Lomis, Nikita
Westfall, Susan
Farahdel, Leila
Malhotra, Meenakshi
Shum-Tim, Dominique
Prakash, Satya
author_sort Lomis, Nikita
collection PubMed
description Human serum albumin nanoparticles (HSA-NPs) are widely-used drug delivery systems with applications in various diseases, like cancer. For intravenous administration of HSA-NPs, the particle size, surface charge, drug loading and in vitro release kinetics are important parameters for consideration. This study focuses on the development of stable HSA-NPs containing the anti-cancer drug paclitaxel (PTX) via the emulsion-solvent evaporation method using a high-pressure homogenizer. The key parameters for the preparation of PTX-HSA-NPs are: the starting concentrations of HSA, PTX and the organic solvent, including the homogenization pressure and its number cycles, were optimized. Results indicate a size of 143.4 ± 0.7 nm and 170.2 ± 1.4 nm with a surface charge of −5.6 ± 0.8 mV and −17.4 ± 0.5 mV for HSA-NPs and PTX-HSA-NPs (0.5 mg/mL of PTX), respectively. The yield of the PTX-HSA-NPs was ~93% with an encapsulation efficiency of ~82%. To investigate the safety and effectiveness of the PTX-HSA-NPs, an in vitro drug release and cytotoxicity assay was performed on human breast cancer cell line (MCF-7). The PTX-HSA-NPs showed dose-dependent toxicity on cells of 52%, 39.3% and 22.6% with increasing concentrations of PTX at 8, 20.2 and 31.4 μg/mL, respectively. In summary, all parameters involved in HSA-NPs’ preparation, its anticancer efficacy and scale-up are outlined in this research article.
format Online
Article
Text
id pubmed-5302621
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53026212017-03-21 Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization Lomis, Nikita Westfall, Susan Farahdel, Leila Malhotra, Meenakshi Shum-Tim, Dominique Prakash, Satya Nanomaterials (Basel) Article Human serum albumin nanoparticles (HSA-NPs) are widely-used drug delivery systems with applications in various diseases, like cancer. For intravenous administration of HSA-NPs, the particle size, surface charge, drug loading and in vitro release kinetics are important parameters for consideration. This study focuses on the development of stable HSA-NPs containing the anti-cancer drug paclitaxel (PTX) via the emulsion-solvent evaporation method using a high-pressure homogenizer. The key parameters for the preparation of PTX-HSA-NPs are: the starting concentrations of HSA, PTX and the organic solvent, including the homogenization pressure and its number cycles, were optimized. Results indicate a size of 143.4 ± 0.7 nm and 170.2 ± 1.4 nm with a surface charge of −5.6 ± 0.8 mV and −17.4 ± 0.5 mV for HSA-NPs and PTX-HSA-NPs (0.5 mg/mL of PTX), respectively. The yield of the PTX-HSA-NPs was ~93% with an encapsulation efficiency of ~82%. To investigate the safety and effectiveness of the PTX-HSA-NPs, an in vitro drug release and cytotoxicity assay was performed on human breast cancer cell line (MCF-7). The PTX-HSA-NPs showed dose-dependent toxicity on cells of 52%, 39.3% and 22.6% with increasing concentrations of PTX at 8, 20.2 and 31.4 μg/mL, respectively. In summary, all parameters involved in HSA-NPs’ preparation, its anticancer efficacy and scale-up are outlined in this research article. MDPI 2016-06-15 /pmc/articles/PMC5302621/ /pubmed/28335244 http://dx.doi.org/10.3390/nano6060116 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lomis, Nikita
Westfall, Susan
Farahdel, Leila
Malhotra, Meenakshi
Shum-Tim, Dominique
Prakash, Satya
Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
title Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
title_full Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
title_fullStr Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
title_full_unstemmed Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
title_short Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization
title_sort human serum albumin nanoparticles for use in cancer drug delivery: process optimization and in vitro characterization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302621/
https://www.ncbi.nlm.nih.gov/pubmed/28335244
http://dx.doi.org/10.3390/nano6060116
work_keys_str_mv AT lomisnikita humanserumalbuminnanoparticlesforuseincancerdrugdeliveryprocessoptimizationandinvitrocharacterization
AT westfallsusan humanserumalbuminnanoparticlesforuseincancerdrugdeliveryprocessoptimizationandinvitrocharacterization
AT farahdelleila humanserumalbuminnanoparticlesforuseincancerdrugdeliveryprocessoptimizationandinvitrocharacterization
AT malhotrameenakshi humanserumalbuminnanoparticlesforuseincancerdrugdeliveryprocessoptimizationandinvitrocharacterization
AT shumtimdominique humanserumalbuminnanoparticlesforuseincancerdrugdeliveryprocessoptimizationandinvitrocharacterization
AT prakashsatya humanserumalbuminnanoparticlesforuseincancerdrugdeliveryprocessoptimizationandinvitrocharacterization